<DOC>
	<DOCNO>NCT00537355</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled , parallel-group , multicenter study . After pass initial Screening Visit , subject environmental exposure chamber ( EEC ) , room control amount ragweed pollen , 4 hour day 4 consecutive day . At last visit , subject achieve minimum Total Nasal Symptom Score ( TNSS ) randomize receive either TOLAMBA placebo treatment . Subjects receive 6 weekly subcutaneous ( skin ) injection study drug . About three week last injection , subject ask EEC 2 consecutive day ( Visits 11 12 , Days 60 61 ) . Approximately 3 week Visit 12 ( Day 61 ) , subject EEC 4 consecutive day ( Visits 13-16 , Days 82-85 ) . During EEC visit , subject expose ragweed pollen average concentration 3500 ± 500 pollen grain per cubic meter . Each EEC visit last 4 hour . During EEC visit , patient ask record symptom score nasal non-nasal symptom schedule time point . The total duration subject 's participation study expect minimum 85 day .</brief_summary>
	<brief_title>An Evaluation Efficacy Safety TOLAMBA™ Ragweed-Allergic Rhinitis Environmental Exposure Chamber</brief_title>
	<detailed_description>Ragweed allergy common seasonal allergy North America . Allergen immunotherapy therapeutic option patient allergy symptom adequately control avoidance allergen medication . It may also appropriate tolerate medication due side effect difficulty medication compliance . This randomized , double-blind , placebo-controlled , parallel-group , multicenter study . After pass initial Screening Visit , subject environmental exposure chamber ( EEC ) , room control amount ragweed pollen , 4 hour day 4 consecutive day . At last visit , subject achieve minimum Total Nasal Symptom Score ( TNSS ) randomize receive either TOLAMBA placebo treatment . Subjects receive 6 weekly subcutaneous ( skin ) injection study drug . About three week last injection , subject ask EEC 2 consecutive day ( Visits 11 12 , Days 60 61 ) . Approximately 3 week Visit 12 ( Day 61 ) , subject EEC 4 consecutive day ( Visits 13-16 , Days 82-85 ) . During EEC visit , subject expose ragweed pollen average concentration 3500 ± 500 pollen grain per cubic meter . Each EEC visit last 4 hour . During EEC visit , patient ask record symptom score nasal non-nasal symptom schedule time point . The total duration subject 's participation study expect minimum 85 day . Comparison : Allergy symptom subject treat TOLAMBA™ compare subject treat placebo .</detailed_description>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic , Seasonal</mesh_term>
	<mesh_term>Histamine</mesh_term>
	<mesh_term>Histamine phosphate</mesh_term>
	<criteria>Is willing able give sign informed consent , must provide consent . Has clinical history seasonal allergic rhinitis seasonal nasal allergy symptom last 2 ragweed allergy season . Has documentation positive skin test ragweed allergen within 12 month screen . Has minimum qualify symptom score last visit PreTreatment EEC session ( Visit 5 , Day 4 ) . If female childbearing potential , pregnant consistently use acceptable birth control method . Is normally active otherwise judge good health basis medical history , physical examination routine laboratory test . A woman pregnant , breastfeeding , plan pregnancy . Has history mild asthma require use daily inhale oral corticosteroid , leukotriene inhibitor , cromolyn ; daily inhale short long act βagonist . Has hospital admission asthma , recent ( within past 12 month ) asthma exacerbation require either oral inhaled corticosteroid , prior history unstable asthma . Has receive immunotherapy within last 2 year contain ragweed pollen extract . Has previously participate clinical trial TOLAMBA another ragweedbased immunotherapy . Has receive immunotherapy allergen within 30 day prior Visit 1 . Has need use antihistamines corticosteroid regular basis ( systemic topical ) . Has receive antiimmunoglobulin E ( IgE ) antibody ( Xolair® ) within past 12 month . Is currently take monoamine oxidase ( MAO ) inhibitor . Has take systemic corticosteroid , immunomodulators , immune suppressive medication within 4 week prior Visit 1 . Has take antihistamine within 7 day prior Visit 1 skin test . Requires use βadrenergic blocker agent may interfere use adrenaline . Known current alcohol drug abuse . Current participation another clinical study involve investigational drug device , participation study within 30 day prior Visit 1 . Has history generalize anaphylaxis require medical attention . Has moderate severe allergy symptom Visit 1 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>ragweed</keyword>
	<keyword>ragweed allergy</keyword>
	<keyword>allergy</keyword>
	<keyword>allergy</keyword>
	<keyword>allergic</keyword>
	<keyword>seasonal allergic rhinitis</keyword>
	<keyword>allergic rhinitis</keyword>
</DOC>